TY - JOUR
T1 - Smart control lipid-based nanocarriers for fine-tuning gut hormone secretion
AU - Xu, Yining
AU - Michalowski, Cécilia Bohns
AU - Koehler, Jackie
AU - Darwish, Tamana
AU - Guccio, Nunzio
AU - Alcaino, Constanza
AU - Domingues, Inês
AU - Zhang, Wunan
AU - Marotti, Valentina
AU - Van Hul, Matthias
AU - Paone, Paola
AU - Koutsoviti, Melitini
AU - Boyd, Ben J.
AU - Drucker, Daniel J.
AU - Cani, Patrice D.
AU - Reimann, Frank
AU - Gribble, Fiona M.
AU - Beloqui, Ana
N1 - Funding Information:
Y.X. was a postdoctoral researcher at UCLouvain (Belgium) and University of Cambridge (UK) supported by the European Research Council (ERC), Wallonie-Bruxelles International (WBI), and Belgian FRS-FNRS (Fonds de la Recherche Scientifique). She is a researcher under grant National Nature Science Foundation of China Excellent Young Scholars Fund (Overseas) and General Program (82370860), the Fundamental Research Funds for the Central Universities (YJ202412), and Department of Science and Technology of Sichuan Province (24YFHZ0326). A.B. is a research associate from the Belgian FRS-FNRS (Fonds de la Recherche Scientifique). A.B. was supported by the FRS-FNRS (convention T.0013.19) and has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement no. 850997-NanoGut). P.D.C. is supported by the Belgian F.R.S.-FNRS (Fonds de la recherche scientifique) under grants The Excellence Of Science (EOS: 40007505), ARC (action de recherche concert\u00E9e: ARC19/24-096), and La Caixa (NeuroGut). N.G. was a UK-MRC-funded PhD student. Work in the Reimann/Gribble laboratory was further supported by grants from Wellcome (220271/Z/20/Z) and the UK Medical Research Council (MC_UU_00014/3) and grants supporting core facilities [supported by the MRC (MRC_MC_UU_00014/5) and Wellcome Trust (100574/Z/12/Z)]. D.J.D. is supported by CIHR grant 154321, a Banting and Best Diabetes Centre Chair in Incretin biology, and a Sinai Health Novo Nordisk Foundation fund in regulatory peptides. All figures were created in BioRender [A.B. (2022), https://BioRender.com/t61t221] and/or GraphPad Prism 9.
Publisher Copyright:
Copyright © 2024 The Authors, some rights reserved.
PY - 2024
Y1 - 2024
N2 - Modulating the endogenous stores of gastrointestinal hormones is considered a promising strategy to mimic gut endocrine function, improving metabolic dysfunction. Here, we exploit mouse and human knock-in and knockout intestinal organoids and show that agents used as commercial lipid excipients can activate nutrient-sensitive receptors on enteroendocrine cells (EECs) and, when formulated as lipid nanocarriers, can bestow biological effects through the release of GLP-1, GIP, and PYY from K and L cells. Studies in wild-type, dysglycemic, and gut Gcg knockout mice demonstrated that the effect exerted by lipid nanocarriers could be modulated by varying the excipients (e.g., nature and quantities), the formulation methodology, and their physiochemical properties (e.g., size and composition). This study demonstrates the therapeutic potential of using nanotechnology to modulate release of multiple endogenous hormones from the enteroendocrine system through a patient-friendly, inexpensive, and noninvasive manner.
AB - Modulating the endogenous stores of gastrointestinal hormones is considered a promising strategy to mimic gut endocrine function, improving metabolic dysfunction. Here, we exploit mouse and human knock-in and knockout intestinal organoids and show that agents used as commercial lipid excipients can activate nutrient-sensitive receptors on enteroendocrine cells (EECs) and, when formulated as lipid nanocarriers, can bestow biological effects through the release of GLP-1, GIP, and PYY from K and L cells. Studies in wild-type, dysglycemic, and gut Gcg knockout mice demonstrated that the effect exerted by lipid nanocarriers could be modulated by varying the excipients (e.g., nature and quantities), the formulation methodology, and their physiochemical properties (e.g., size and composition). This study demonstrates the therapeutic potential of using nanotechnology to modulate release of multiple endogenous hormones from the enteroendocrine system through a patient-friendly, inexpensive, and noninvasive manner.
U2 - 10.1126/sciadv.adq9909
DO - 10.1126/sciadv.adq9909
M3 - Journal article
C2 - 39671480
AN - SCOPUS:85212660146
VL - 10
JO - Science advances
JF - Science advances
SN - 2375-2548
IS - 50
M1 - eadq9909
ER -